MENU
Advertisement
Show Filters
Refine by Content Type
Refine by Year
Sort By:
Choose Sites to Search:
Portomesenteric Intervention in the Cancer Patient
A review of patient selection and treatment approaches.
By Joshua D. Kuban, MD; Armeen Mahvash, MD; and Rahul A. Sheth, MD
Sirtex Commences DOORwaY-90 Study for SIR-Spheres Therapy as First-Line Treatment of Unresectable HCC
May 10, 2021—Sirtex Medical announced that the first patient has been enrolled in the DOORwaY-90 study evaluating the safety and efficacy of selective internal radiation therapy using the company’s SIR-Spheres yttrium-90 (Y-90) resin microspheres in patients with unresectable hepatocellular carcinoma.
Exploring New Dimensions of Interventional Oncology
By Rahul A. Sheth, MD, and Alda L. Tam, MD, MBA, FSIR
Sirtex’s SIR-Spheres Approved to Treat Unresectable HCC
July 7, 2025—Sirtex Medical announced that the FDA has approved the company’s SIR-Spheres yttrium-90 (Y90) resin microspheres for the treatment of unresectable hepatocellular carcinoma (HCC) in the United States.
Sirtex SIR-Spheres Evaluated in DOORwaY90 Pivotal Trial to Treat Unresectable HCC
April 13, 2026—Sirtex Medical announced that its landmark pivotal DOORwaY90 trial met its 12-month prespecified coprimary endpoints, demonstrating a 90% complete response rate and an overall response rate of 99%, as assessed by blinded independent central review.
Sirtex Medical Receives FDA Approval to Conduct DOORwaY90 Study of SIR-Spheres in Unresectable HCC
March 22, 2021––Sirtex Medical announced full FDA approval of the DOORwaY90 study, which is evaluating the safety and efficacy of selective internal radiation therapy (SIRT) using the company’s SIR-Spheres yttrium-90 (Y-90) resin microspheres in patients with unresectable hepatocellular carcinoma (HCC).
